Speakers - Sachs Associates

More documents

Recommendations

Info

<strong>Speakers</strong> Rudi Neirinckx, CEO, Ennar Pharma Rudi is an experienced pharmaceutical industry executive, with a record of invention, being the author of over 100 scientific publications and more than a dozen patents. He worked in most aspects of the pharmaceutical business, i.e. research, clinical development, licensing, business development, etc. in the diagnostic as well as the therapeutic side of the business. After an academic career in Nuclear Medicine and Radiology he headed up the R&D operations of Amersham International (UK) and Serono (Geneva), but also was responsible for reorganizing the M&A Department of Merck KGaA, where he made numerous license and M&A deals, including a deal with Imclone Systems. He founded an OTC Company (Agys Pharma, Belgium), based on his invention of an effective treatment of dental sensitivity and was COO of a Generics Company (PAR Pharmaceuticals, USA), which he helped turn around. He also was CEO of atugen, a Berlin high-tech start-up, before he became a full-time consultant to the President of Altana Pharma. Subsequently he has exclusively worked on the psoriasis project, which is now handled at Ennar Pharma AG. Sarah Holland, Global Head, Strategic Partnering, Roche Partnering Sarah Holland is the Global head, Strategic Partnering for Roche Partnering based in Basel, Switzerland. Her team’s projects include broad strategic landscapes of M&A and late stage opportunities, transactional support for all pharma M&A transactions, initiatives to generate income through divestments, spin-outs and strategic partnerships, and development and delivery of creative deal structures to address key business needs. In 2010 the team acquired world-wide rights to danoprevir from Intermune and supported the acquisition of Marcadia Biotech. Since joining Roche in 2005, Sarah has held various responsibilities in business development, such as Global Head of CNS Partnering, and has led projects in a range of disease areas, including the Plexxikon deal on b-raf inhibitors. Prior to joining Roche, Sarah was Global Brand Director at AstraZeneca for a hormonal agent for breast cancer during US and EU launch. She held various commercial and strategic roles over her ten years there, including Global Strategic Planning Manager for early compounds, Pricing Strategist and Health Economist. Before AstraZeneca, she held local and international sales and marketing roles in diagnostics, biotech and pharmaceutical companies. Sarah gained her MBA from Manchester Business School, where she was a Visiting Fellow until 2004, and her D.Phil and first degree at Oxford University. Scott Cuthill, Director, Corporate Business Development Team, Ipsen Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees. Simon Nebel, Managing Partner, Aravis Since joining Aravis in 2001, Simon has participated in the financing of a number of life science companies and the M&A transactions of a number of Aravis portfolio companies. Most recently he was a co-founder of Aravis Energy I LP, the first Swiss Limited Partnership focused on renewable energy. Before joining Aravis, Simon was a group strategist at UBS (London, Basel and Zurich), where he coordinated and worked on business planning and modelling. This included developing a Biotechnology Venture Capital business proposal for UBS Capital. He is currently a board member of MarinoMed, ImVision and MerLion Pharmaceutical SA and Leading Swiss Renewable Energy AG as well as an observer on the board of Anaphore (USA), and a former member of the board of directors of Borean Pharma (Denmark) and secretary of the board of Evolva (Switzerland). Simon holds a PhD in Biophysics from the Biocentre of the University of Basel (1996) and an MBA with distinction from the London Business School (2001). t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
<strong>Speakers</strong> Søren Moller, Managing Investment Director, Novo A/S Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark for a project on molecular microbiology. In addition to his PhD, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine. Prior to joining Novo Seeds, Søren served as global manager of Bioinformatics and Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S where he was responsible for development of microRNA based products for life science research, pharma services and diagnostics. In 2007 Exiqon completed an IPO on NASDAQ OMX Copenhagen raising 400 mio DKK to develop and commercialize life science and diagnostic products. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk. Since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark). Søren serves on the board of directors of Denator AB, a Swedish based biotech company. Stephanie Leouzon, Senior Advisor, Torreya Partners Stephanie is a Senior Advisor at Torreya Partners, a life sciences advisory boutique. She has worked in Health Care Investment Banking since 1989, participating in over 65 transactions in the biotechnology, pharmaceutical and speciality pharmaceutical sectors. She has advised clients on a number of strategic transactions, valued at over $70 billion, and she has been involved in financing transactions to provide over $7 billion to healthcare clients. Prior to joining Credit Suisse in 1998, Stephanie’s experience included working in Health Care at Lehman Brothers, JP Morgan and Salomon Brothers (now Citigroup). Stephanie earned an M.B.A. degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a B.A. degree, cum laude, from Mount Holyoke College in 1985. Thomas Kronbach, CEO, BioCrea GmbH Thomas is CEO of BioCrea, a drug discovery company in Radebeul, Germany, which is creating first-in-class drugs from concept to drug candidate. Tom established BioCrea as a Management buy-out of assets from Biotie Therapies in 2010. Previously, Tom was CSO of Biotie Therapies, CSO and founder of elbion and had various positions at Asta Medica, AWD and Goedecke. Tom has initiated, negotiated and fostered partnerships with Boehringer Ingelheim, Wyeth/Pfizer and GlaxoSmithKline. Tom holds a Ph.D. from the University of Tubingen, Germany, was a Post Doctoral Fellow at the University of Basle, Switzerland and a Research Associate at The Scripps Clinic and Research Foundation in La Jolla, CA. Tim Haines, Partner, Abingworth Management Tim has more than 25 years of international management experience in the life sciences industry including significant expertise in medical devices. Before joining Abingworth in 2005, he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe. At Abingworth, he identifies and creates new businesses and provides support for existing companies within the Abingworth portfolio. He is or has been a board member of the following portfolio companies: Astex Therapeutics, Powdermed (acquired by Pfizer), IMI, Stanmore Orthopedic, Fovea (acquired by sanofi-aventis), KSpine, XCounter (AIM) and Chroma Therapeutics. Tom Johnston, CEO, Mucosis BV In his role he has global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21: Speakers Richard Goodfellow, CEO, S
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74:
CONTACTS General and Media Contact
Page 75 and 76:
CONTACTS Martin Welschof Chief Exec
Page 77 and 78:
CONTACTS Carlos Buesa Chief Executi
Page 79 and 80:
CONTACTS Nick McCooke Chief Executi
Page 81 and 82:
CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84:
CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86:
CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?